Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. - Wikidata - wikimedia - TriplyDB

Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.

Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.

http://www.wikidata.org/entity/Q34534574

about

Sunitinib in the treatment of metastatic renal cell carcinoma Is there a role for systemic targeted therapy after surgical treatment for metastases of renal cell carcinoma?Immunotherapy for metastatic renal cell carcinoma.Renal cell cancer: overview of the current therapeutic landscape.Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus.Adjuvant therapy for locally advanced renal cell cancer: a systematic review with meta-analysis Recent updates in renal cell carcinoma Adjuvant therapy for renal cell carcinoma: past, present, and future Expression and clinical significance of cancer-testis genes in clear cell renal cell carcinoma.The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (D The prospects of pazopanib in advanced renal cell carcinoma.Tumor heterogeneity as a rationale for a multi-epitope approach in an autologous renal cell cancer tumor vaccine Renal cell carcinoma and the use of sorafenib.Systemic adjuvant therapies in renal cell carcinoma Akt inhibitors in clinical development for the treatment of cancer.Vaccination immunotherapy--an update.Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma.Adjuvant therapy of renal cell carcinoma: patient selection and therapeutic options.Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?Choices in adjuvant therapy of melanoma.Adjuvant treatment for renal cell carcinoma.Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma.Management of locally advanced renal cell carcinoma.Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial.New drug therapies for advanced renal cell carcinoma.Age at diagnosis is a determinant factor of renal cell carcinoma-specific survival in patients treated with nephrectomy.Growing opportunities for adjuvant therapy of renal cell carcinoma: targeted drugs and vaccines.Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.Sunitinib therapy in renal cell carcinoma.Adjuvant therapy in renal cell carcinoma-past, present, and future.Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma.Predicting growth of solid renal masses under active surveillance.Recent developments in the treatment of renal cell carcinoma.Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.Adjuvant and neoadjuvant therapy in renal cell carcinoma.Multimodality treatment paradigms for renal cell carcinoma: surgery versus targeted agents.Can vaccination or tyrosine kinase inhibitor therapy play a role in the adjuvant treatment of renal cell carcinoma?New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib.Systemic therapy for advanced renal cell carcinoma.

P2860

Q28072057-8CA07E32-8727-4738-B01F-9594EAE58CEC Q28087518-08A04353-F20D-429C-872F-89998A485793 Q30234458-D840FC3E-FF94-4739-9155-EDA3ACE7F64F Q30248354-56F8273E-FE84-4F88-B473-21109FB0F218 Q33843677-95C5A575-E0F8-4437-9ADD-7F9E1CB6935B Q33858807-02CC5BF4-0B67-4775-9D3C-9AC5BAA09430 Q34003369-4E0A2F6E-90BC-4653-BAC2-9FE055EA8CBD Q34005127-66715241-D819-432E-9038-E28608075C04 Q34029148-15BB6F1C-DDA6-437C-A1F5-9E07C8175579 Q34186886-0F192D84-0089-4389-9EDA-1D9BB0D482A4 Q34555854-3AD8E9E5-61AC-4948-9623-5F75C78BAF47 Q34656393-B1B75012-BF9E-4727-B465-764EA9CBAAFF Q34675774-D531D083-D07F-4912-B343-0FD24665D522 Q35166782-0EBA5918-223C-4F32-86E7-C78817304E49 Q35569322-23D1DD9A-CD1E-4FFE-A825-6F183AE2F9E1 Q35628576-9868743A-0926-428E-B850-28DCF8D58659 Q35851700-89A82EB3-4DA8-4833-B023-1C916F0E6CFF Q35916894-ADEBFEEA-CEBF-44E3-A68D-DFB2222753A0 Q36232195-1F7C35E5-92EF-4BE5-9E53-8192816DBEE4 Q36291489-4BF7F36A-DC7E-4683-B98C-0E0042E90CBE Q36301110-C922B082-A47B-4F15-B0CE-5E8B5B197014 Q36429718-9DEA57B0-9D21-4617-B961-248C175FEF14 Q36491239-F03E5AA5-0F22-4537-8BB7-C285C2BC6554 Q36555667-A170A06D-B918-4C2D-897D-AB00EC1C0D68 Q36611853-50B9FB32-31A8-49C5-A059-B535C2422614 Q36691810-3A09EA2B-0F45-4977-B5CC-82BD27618831 Q36995364-77F1BFE1-EAE2-43F2-8817-941EBB9B048F Q37000740-131ECED3-D270-49A6-A5A0-F1E70B0B1407 Q37071204-9513264D-DE76-4FD1-BB20-2D0C2CDBBBAC Q37088460-E699BBFE-62AD-42D0-A378-72A1938E03DF Q37153437-1ECDC852-00C2-42A7-9B00-5E33FF0A19E3 Q37205794-E5905C38-B922-4B34-86F2-4B89529338BE Q37287106-59C3A354-E481-46B6-899D-738128E383FF Q37300942-39747E0A-F93C-427F-9CFB-45FBBEBC2740 Q37414808-102BB5B2-7DC0-4643-8998-146F35619590 Q37492442-68DB6C1D-13A3-4405-A32D-DD80AF74D5AD Q37508012-D7D20677-FF30-472A-A5F8-F63FC5DD3D86 Q37765583-5B0294B5-1E37-4292-8B34-BA9390D8A248 Q37806966-EDE952FE-BD6D-4857-AC54-9C853A6B3988 Q37905583-D8692FE9-5799-45AF-A040-688652196CA1

P2860

Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.

http://www.wikidata.org/entity/Q34534574

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Adjuvant high-dose bolus inter ...... orking group randomized trial.

@ast

Adjuvant high-dose bolus inter ...... orking group randomized trial.

@en

Adjuvant high-dose bolus inter ...... orking group randomized trial.

@nl

type

label

Adjuvant high-dose bolus inter ...... orking group randomized trial.

@ast

Adjuvant high-dose bolus inter ...... orking group randomized trial.

@en

Adjuvant high-dose bolus inter ...... orking group randomized trial.

@nl

prefLabel

Adjuvant high-dose bolus inter ...... orking group randomized trial.

@ast

Adjuvant high-dose bolus inter ...... orking group randomized trial.

@en

Adjuvant high-dose bolus inter ...... orking group randomized trial.

@nl

P1433

Q34534574-F3CAA400-6208-44F6-9240-851BE0B07ACE

P1476

Q34534574-03E67C43-7D0C-4571-B257-079F745B3527

P2093

Q34534574-031D6663-D957-43FD-9792-C3EFDA131DC4

Q34534574-1FDACCF6-1BFC-4953-BF02-645C6DC21D93

Q34534574-27E33FC7-A450-46ED-9B85-14DB039B09C0

Q34534574-389D2F71-26DE-48B2-BB74-AD6AF5390A3A

Q34534574-469661CF-564A-4308-824D-B5CA48DB8138

Q34534574-556A15D3-68FD-4513-AAEB-6F72AF3C096D

Q34534574-5DB25072-EA42-4454-9C0C-8C737E65B691

Q34534574-63A51042-D7BF-464E-BA68-55E1D1913F95

Q34534574-77978A28-FDB2-486D-AD49-00FEE637C363

Q34534574-8B993FC0-441C-48D8-AB46-DF23D4C6D487

P304

Q34534574-03881472-CEFE-4CBD-AF66-CA69A53D80EC

P31

Q34534574-B8363AF8-B5FD-4BA6-908D-401FAC296236

P356

Q34534574-150C464C-2EAE-475F-AB69-074C55E3E896

P407

Q34534574-929D392F-9757-4E43-BEB6-D97F0665E790

P433

Q34534574-75EBF416-7EC7-42BE-A4F2-51868197ED1A

P478

Q34534574-2945FF8C-1433-4644-B31E-C951716CECC8

P577

Q34534574-8F3367F2-6A80-4E87-852F-95E590945490

P698

Q34534574-EACF27B5-AA4E-43BD-B1C2-B3E774DF280A

P921

Q34534574-e463b072-bab3-4a44-b922-2ee3a937e73e

P356

JCO.2003.02.014

P1433

Journal of Clinical Oncology

P1476

Adjuvant high-dose bolus inter ...... orking group randomized trial.

@en

P2093

Bruce G Redman

http://www.w3.org/2001/XMLSchema#string

Christopher P G Tretter

http://www.w3.org/2001/XMLSchema#string

David McDermott

http://www.w3.org/2001/XMLSchema#string

Geoffrey R Weiss

http://www.w3.org/2001/XMLSchema#string

Janice P Dutcher

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Sosman

http://www.w3.org/2001/XMLSchema#string

John W Smith

http://www.w3.org/2001/XMLSchema#string

Joseph I Clark

http://www.w3.org/2001/XMLSchema#string

Kim A Margolin

http://www.w3.org/2001/XMLSchema#string

Larry Flaherty

http://www.w3.org/2001/XMLSchema#string

P304

3133-3140

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2003.02.014

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2003-06-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12810695

http://www.w3.org/2001/XMLSchema#string

P921